Eli Lilly & Co. (LLY) Tops Q4 EPS by 34c, Beats on Revenue; Offers FY26 Guidance

Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $7.54, $0.34 better than the analyst estimate of $7.20. Revenue for the quarter came in at $19.3 billion versus the consensus estimate of $17.87 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2026 EPS of $33.50-$35.00, versus the consensus of $33.30. Eli Lilly & Co. sees FY2026 revenue of $80-83 billion, versus the consensus of $77.6 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Krait Critical Minerals closes $1.22M first tranche of placement
• NeuroSense posts narrower H1 loss, targets Canada drug filing by December